0001193125-18-317313.txt : 20181102 0001193125-18-317313.hdr.sgml : 20181102 20181102170104 ACCESSION NUMBER: 0001193125-18-317313 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20181102 FILED AS OF DATE: 20181102 DATE AS OF CHANGE: 20181102 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Ascendis Pharma A/S CENTRAL INDEX KEY: 0001612042 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: G7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36815 FILM NUMBER: 181157820 BUSINESS ADDRESS: STREET 1: TUBORG BOULEVARD 12 CITY: HELLERUP STATE: G7 ZIP: DK-2900 BUSINESS PHONE: 45 70 22 22 44 MAIL ADDRESS: STREET 1: TUBORG BOULEVARD 12 CITY: HELLERUP STATE: G7 ZIP: DK-2900 6-K 1 d644355d6k.htm 6-K 6-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO SECTION 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November, 2018

Commission File Number: 001-36815

 

 

Ascendis Pharma A/S

(Exact Name of Registrant as Specified in Its Charter)

 

 

Tuborg Boulevard 12

DK-2900 Hellerup

Denmark

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☒                Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

 

 

 

INCORPORATION BY REFERENCE

This report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form S-8 (Registration Numbers 333-203040, 333-210810, 333-211512, 333-213412, 333-214843 and 333-216883) and Form F-3 (Registration Numbers 333-209336, 333-211511, 333-216882, 333-223134 and 333-225284) of Ascendis Pharma A/S (“Ascendis” or the “Company”) (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

 

 

Annual General Meeting Results

On November 2, 2018, Ascendis held an Extraordinary General Meeting. 27,880,670 ordinary shares of Ascendis (which includes 26,878,454 ordinary shares represented by American Depositary Shares), representing in total 66.33% of the ordinary shares outstanding as of the date of the Extraordinary General Meeting, were voted at the meeting. The final results of each of the agenda items submitted to a vote of the shareholders are as follows:

Agenda Item 1: Election of Chairman of the Meeting

Ascendis shareholders elected Anders Carstensen as chairman of the meeting.

Agenda Item 2: Election of new Board Member

Ascendis shareholders elected Lars Holtug as a Class II director, with the term for such board member to expire at the Annual General Meeting of the Company to be held in 2020.

Agenda Item 3: Authorization of the Chairman of the meeting

Ascendis shareholders authorized the chairman of the meeting (with a right of substitution) on behalf of the Company to apply to the Danish Business Authority for registration of the resolutions passed and to make any such amendments and supplements to the application and the resolutions, including the Company’s articles of association and these minutes of the general meeting, as may be required as a condition for registration.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    Ascendis Pharma A/S
Date: November 2, 2018     By:  

/s/ Michael Wolff Jensen

    Michael Wolff Jensen
    Chairman and Senior Vice President, General Counsel